OSR Holdings

OSR Holdings continues to develop pipelines in varied therapeutic areas. Vaximm is developing a versatile proprietary platform directing cytotoxic T-cells against a wide range of epitopes with p.o. dosing. VXM01 is a clinical stage VEGFR-2 inhibitor with pre-clinically proven anti-angiogenic activity, and encouraging Phase 1/2 safety profile in pancreatic cancer and GBM. Development expansion into other oncology and non-oncology indications is currently being investigated.

Meanwhile the Darnatein platform is a synthetic biology platform employing AI to generate “hybrid” versions of endogenous proteins with superior activity and excellent safety profile. Lead asset DRT-101 is engineered to function as BMP super-agonist for joint cartilage regeneration, targeting OA with huge unmet medical need and potential as a DMOAD. DRT-101 is targeting 2026 IND submission in Korea and subsequent submissions to other regulatory agencies to follow (EU, US). At the same time, DRT-102 has applications in bone fusion, and is already in clinical studies in South Korea. DRT-102 is already shown to have an excellent safety profile with efficacy data.

More details of our Subco respective pipelines are available at:
Vaximm -- https://vaximm.com/pipeline

Darnatein -- https://darnatein.com/Pipeline

Woori IO -- https://woori-io.imweb.me/

OSR Holdings continues to develop pipelines in varied therapeutic areas. Vaximm is developing a versatile proprietary platform directing cytotoxic T-cells against a wide range of epitopes with p.o. dosing. VXM01 is a clinical stage VEGFR-2 inhibitor with pre-clinically proven anti-angiogenic activity, and encouraging Phase 1/2 safety profile in pancreatic cancer and GBM. Development expansion into other oncology and non-oncology indications is currently being investigated.

Meanwhile the Darnatein platform is a synthetic biology platform employing AI to generate “hybrid” versions of endogenous proteins with superior activity and excellent safety profile. Lead asset DRT-101 is engineered to function as BMP super-agonist for joint cartilage regeneration, targeting OA with huge unmet medical need and potential as a DMOAD. DRT-101 is targeting 2026 IND submission in Korea and subsequent submissions to other regulatory agencies to follow (EU, US). At the same time, DRT-102 has applications in bone fusion, and is already in clinical studies in South Korea. DRT-102 is already shown to have an excellent safety profile with efficacy data.

More details of our Subco respective pipelines are available at:
Vaximm -- https://vaximm.com/pipeline

Darnatein -- https://darnatein.com/Pipeline

Woori IO -- https://woori-io.imweb.me/